V. D. de Jesus

发表

Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma.

V. D. de Jesus, M. Camandaroba, M. Donadio, 2018, Journal of gastrointestinal oncology.

Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center

V. D. de Jesus, F. Coimbra, A. Diniz, 2018, World Journal of Surgical Oncology.

Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience

V. D. de Jesus, M. Camandaroba, A. Dettino, 2019, Therapeutic advances in medical oncology.

Opportunistic and Serious Infections in Patients with Neuroendocrine Tumors Treated with Everolimus: A Multicenter Study of Real-World Patients

R. Riechelmann, F. Costa, V. D. de Jesus, 2020, Neuroendocrinology.

Role of staging laparoscopy in the management of Pancreatic Duct Carcinoma (PDAC): Single‐center experience from a tertiary hospital in Brazil

V. D. de Jesus, F. Coimbra, A. Diniz, 2018, Journal of surgical oncology.

Short‐term outcomes after vascular resection for pancreatic tumors: Lessons learned from 72 cases from a single Brazilian Cancer Center

V. D. de Jesus, F. Coimbra, A. Diniz, 2019, Journal of surgical oncology.

Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer

R. Riechelmann, V. Calsavara, V. D. de Jesus, 2020, Therapeutic advances in medical oncology.

Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms

R. Riechelmann, L. Claro, V. D. de Jesus, 2022, Journal of neuroendocrinology.

M. P. de Macedo, M. Begnami, V. D. de Jesus, 2015, BMC Cancer.

Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies

R. Riechelmann, V. D. de Jesus, T. Felismino, 2018, Clinics.

Is primary sidedness a prognostic factor in patients with resected colon cancer liver metastases (CLM)?

R. Riechelmann, M. P. de Macedo, V. D. de Jesus, 2018, Journal of surgical oncology.

Disparities in access to health care system as determinant of survival for patients with pancreatic cancer in the State of São Paulo, Brazil

R. Riechelmann, M. Curado, L. Claro, 2021, Scientific Reports.

Primary Tumor Location Is a Predictor of Poor Prognosis in Patients with Locally Advanced Esophagogastric Cancer Treated with Perioperative Chemotherapy

R. Riechelmann, F. Coimbra, C. A. D. de Mello, 2019, Journal of Gastrointestinal Cancer.

Survival outcomes of patients with pathological stage I gastric cancer using the competing risks survival method.

V. Calsavara, V. D. de Jesus, F. Coimbra, 2019, Journal of gastrointestinal oncology.

Early metabolic 18F-FDG PET/CT response of locally advanced squamous-cell carcinoma of head and neck to induction chemotherapy: A prospective pilot study

L. Kowalski, V. Calsavara, P. N. Barbosa, 2018, PloS one.

Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist’s Perspective

R. Riechelmann, V. D. de Jesus, 2023, Cancer control : journal of the Moffitt Cancer Center.

Clinical factors related to severe enterocolitis after adjuvant CAPOX for colorectal cancer: a retrospective analysis

R. Riechelmann, C. A. D. de Mello, V. D. de Jesus, 2020, Ecancermedicalscience.

Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)

V. D. de Jesus, A. Dettino, 2018, Journal of hepatocellular carcinoma.

Evaluation of prognostic factors in patients undergoing first-line chemotherapy for advanced biliary tract cancer: a retrospective analysis from a South American cancer centre

R. Riechelmann, V. D. de Jesus, T. Felismino, 2022, Ecancermedicalscience.

Therapy Sequencing in Patients With Advanced Neuroendocrine Neoplasms.

R. Riechelmann, M. Iglesia, N. Trikalinos, 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Disease-Free Survival and Time to Complete Response After Definitive Chemoradiotherapy for Squamous-Cell Carcinoma of the Anus According to HIV Infection.

R. Riechelmann, V. Silva, V. D. de Jesus, 2020, Clinical colorectal cancer.

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis

R. Riechelmann, V. D. de Jesus, 2021, Ecancermedicalscience.

Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX.

V. D. de Jesus, M. Camandaroba, M. Donadio, 2018, Journal of gastrointestinal oncology.

Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas

J. L. Fleck, G. Kinker, R. Weinlich, 2023, Gut.

HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors

R. Riechelmann, J. Strosberg, V. D. de Jesus, 2023, Therapeutic advances in medical oncology.

Current clinical practice in the management of Brazilian patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC).

R. Riechelmann, V. D. de Jesus, R. Weschenfelder, 2023, Journal of surgical oncology.

Short-term survival of patients with advanced pancreatic cancer admitted to intensive care unit: a retrospective cohort study

A. P. Nassar, V. D. de Jesus, M. Camandaroba, 2022, Ecancermedicalscience.